Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. [electronic resource]
Producer: 20101221Description: 2655-65 p. digitalISSN:- 1524-4636
- Adult
- Aged
- Angioplasty, Balloon, Coronary -- adverse effects
- Biomarkers -- blood
- Blood Glucose -- metabolism
- Cardiovascular Agents -- administration & dosage
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Cells, Cultured
- Chemokine CCL2 -- blood
- Coronary Angiography
- Coronary Artery Disease -- blood
- Coronary Restenosis -- etiology
- Coronary Vessels -- diagnostic imaging
- Diabetes Mellitus, Type 2 -- blood
- Dose-Response Relationship, Drug
- Drug-Eluting Stents
- Female
- Glycated Hemoglobin -- metabolism
- Humans
- Hyperplasia
- Hypoglycemic Agents -- therapeutic use
- Inflammation Mediators -- blood
- Insulin -- blood
- Interleukin-6 -- blood
- Killer Cells, Natural -- drug effects
- Lipids -- blood
- Male
- Middle Aged
- Myocytes, Smooth Muscle -- drug effects
- Pioglitazone
- Prospective Studies
- Prosthesis Design
- Receptors, CCR2 -- blood
- Republic of Korea
- Single-Blind Method
- Sirolimus -- administration & dosage
- Thiazolidinediones -- therapeutic use
- Time Factors
- Treatment Outcome
- Tunica Intima -- diagnostic imaging
- Ultrasonography, Interventional
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.